News

OIS-Eye-On-Five

Eye on Five – January Edition

By Rich Kirkner | February 1, 2017

Alcon Turnaround Has Novartis Exploring Spin-off With its Alcon turnaround plans on track, Novartis AG revealed it is exploring options that include spinning off Alcon…

Read More

Alcon Turnaround Has Novartis Exploring Spin-off

By Rich Kirkner | January 26, 2017

In announcing that Novartis AG is exploring spinning off its Alcon eye-care business, Novartis CEO Joseph Jimenez acknowledged that Alcon has made progress in the…

Read More

Is Trump Opening New Front in War on Drug Prices?

By Rich Kirkner | January 18, 2017

Pharma executives were beaming as their stock prices soared in the days after Donald Trump’s poll-defying victory, and their sentiments rose even higher with the…

Read More
After Phase III Disappoints, Inotek Looks to Fixed-Dose Combination - Eye On Innovation - OIS

After Phase III Disappoints, Inotek Looks to Fixed-Dose Combination

By Rich Kirkner | January 11, 2017

As Inotek Pharmaceuticals sifts through the disappointing Phase III top-line results for its lead clinical candidate trabodenoson and the 66% stock price slide that followed,…

Read More

OIS Index Underperforms Benchmarks in First Quarter Since Inception

By Michael Lachman | January 5, 2017

In October, OIS partnered with EyeQ Research to launch the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our…

Read More
Eye On Innovation Article - After stunning Phase 3 results, Ophthotech seeks a path forward - Healthegy

After Stunning Phase III Results, Ophthotech Seeks a Path Forward

By Rich Kirkner | December 15, 2016

After disappointing Phase III results of Fovista (pegpleranib) in combination with Lucentis (ranibizumab, Genentech) sent its stock reeling, Ophthotech Corporation is reevaluating not only the…

Read More
What’s Next for Sun Ophthalmics after BromSite Launch? - OIS - Eye On Innovation Article - Healthegy

What’s Next for Sun Ophthalmics After BromSite Launch?

By Rich Kirkner | December 7, 2016

With the launch last week of BromSite to treat inflammation and prevent pain after cataract surgery, India-based Sun Pharma has taken a significant step in…

Read More
OIS - Eye on Five

Eye on Five – November Edition

By Rich Kirkner | November 30, 2016

Trump Bump Fuels Biotech, Pharma Stocks Pharma and biotech stocks surged in the week after Donald Trump’s election, with the OIS Index jumping 13% and…

Read More
part-two-three-novel-partnerships-11-30-16

Three Novel Partnerships in Ophthalmology (Part Two)

By Michael Smolinsky | November 30, 2016

Two weeks ago, we began reviewing collaborations between ophthalmic start-ups and institutions or groups that traditionally haven’t been involved in developing medical technology, such as…

Read More
As Novartis Ponders Alcon’s Sale, Who Is Best Owner?

As Novartis Ponders Alcon’s Sale, Who Is Best Owner?

By Larry Haimovitch | November 22, 2016

So when does a rumor cease being a rumor and become a reality? It remains to be seen whether all the recent and persistent rumors…

Read More
OIS Index Follows Biotech Stocks Lower in October - OIS Index - Healthegy

OIS INDEX: Trump Bump

By Michael Lachman | November 16, 2016

The OIS Index closed at 962.42 on Tuesday, a week after Donald Trump’s election. Here’s how the collection of 29 publicly traded ophthalmology companies fared…

Read More
biotech-biopharma-takeaways-from-the-election-11-16-16

Biotech, Biopharma Takeaways from the Election

By Rich Kirkner | November 16, 2016

In the wake of Donald Trump’s surprise election last week, and with the GOP maintaining firm control of Congress, pharma and biotech stocks have witnessed…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.